As compared to GFP- cells, GFP+ cells exhibited increased migration (Fig. 4A; Appendix Fig. S5A) and invasion potential (Fig. 4B; Appendix Fig. S5B), and decreased sensitivity to trametinib, a MEK inhibitor used in the clinic to treat melanoma (Fig. 4C; Appendix Fig. S5C). The gene discussed is MAP2K7; the disease is melanoma.